» Articles » PMID: 6321671

Evaluation of Prognostic Factors in Chemotherapy of Recurrent Brain Tumors

Overview
Journal J Clin Oncol
Specialty Oncology
Date 1983 Jan 1
PMID 6321671
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

We have evaluated the prognostic significance of several easily obtainable and commonly used factors in patients with primary brain tumors (recurrent after irradiation) undergoing chemotherapy. Age, sex, tumor grade, on-study performance score, time from initial diagnosis to initial postirradiation progression, and prior chemotherapy or no were evaluated for affects on tumor response. None of the six factors significantly correlated with response to therapy. The above six factors plus response to chemotherapy were evaluated for their affects on time to progression and survival. Tumor regression following chemotherapy most strongly correlated with prolonged time to progression and survival. A good on-study performance score (not, or only minimally, symptomatic) significantly correlated with prolonged survival, but not with prolonged time to progression. Surprisingly, tumor grade did not significantly correlate with response, time to progression, or survival. Further study is required, but initial data analyses would suggest that essentially all patients with all grades of recurrent tumor could be used in chemotherapeutic trials with proper pretreatment stratification.

Citing Articles

Immune Landscape in PTEN-Related Glioma Microenvironment: A Bioinformatic Analysis.

Lucifero A, Luzzi S Brain Sci. 2022; 12(4).

PMID: 35448032 PMC: 9029006. DOI: 10.3390/brainsci12040501.


Against the Resilience of High-Grade Gliomas: Gene Therapies (Part II).

Lucifero A, Luzzi S Brain Sci. 2021; 11(8).

PMID: 34439595 PMC: 8393930. DOI: 10.3390/brainsci11080976.


Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I).

Lucifero A, Luzzi S Brain Sci. 2021; 11(3).

PMID: 33803885 PMC: 8003180. DOI: 10.3390/brainsci11030386.


Improving vaccine efficacy against malignant glioma.

Ladomersky E, Genet M, Zhai L, Gritsina G, Lauing K, Lulla R Oncoimmunology. 2016; 5(8):e1196311.

PMID: 27622066 PMC: 5007967. DOI: 10.1080/2162402X.2016.1196311.


Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials.

Carson K, Grossman S, Fisher J, Shaw E J Clin Oncol. 2007; 25(18):2601-6.

PMID: 17577040 PMC: 4118746. DOI: 10.1200/JCO.2006.08.1661.